Evidence map›Paper›PMID 40266400›Full record

ArticleSurgery today2025

Association between the preoperative Midkine (+)/CEA (+) level and poor prognosis in colorectal cancer patients.

Mitsunori Ushigome, Hideaki Shimada, Masaaki Ito, Kimihiko Yoshida, Takayuki Suzuki, Satoru Kagami, Yasuyuki Miura, Tomoaki Kaneko, Akiharu Kurihara, Kimihiko Funahashi

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mitsunori UshigomeDepartment of Surgery, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.
Hideaki ShimadaDepartment of Surgery, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan. hideaki.shimada@med.toho-u.ac.jp.ORCID http://orcid.org/0000-0002-1990-8217
Masaaki ItoDepartment of Surgery, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.
Kimihiko YoshidaDepartment of Surgery, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.
Takayuki SuzukiDepartment of Surgery, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.
Satoru KagamiDepartment of Surgery, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.
Yasuyuki MiuraDepartment of Surgery, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.
Tomoaki KanekoDepartment of Surgery, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.
Akiharu KuriharaDepartment of Surgery, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.
Kimihiko FunahashiDepartment of Surgery, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo, 143-8541, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the clinicopathological and prognostic significance of preoperative serum Midkine levels in patients with colorectal cancer.

methodsPreoperative Midkine levels were analyzed using an enzyme-linked immunosorbent assay in 78 patients with colorectal cancer, at stages 0 (n = 2), I (n = 19), II (n = 25), III (n = 24), and IV (n = 8). Using a cut-off value of 421 pg/mL, the patients were divided into a Midkine(+) group and a Midkine(-) group. Clinicopathological factors and prognosis were compared between the two groups, using univariate and multivariate analyses.

resultsThe overall positive rates were 46%, 32%, and 21% for CEA, Midkine, and CA19-9, respectively. The positive rate of the Midkine/CEA combination was 55%. The positive rates at stage 0/I were 19%, 19%, and 5% for CEA, Midkine, and CA19-9, respectively. The Midkine(+) group showed poor survival, but the differences were not significant. The Midkine (+)/CEA (+) group had significantly worse relapse-free survival (RFS) (p = 0.02). The Midkine (+)/CEA (+) level was an independent risk factor for RFS (p = 0.04) and overall survival (p = 0.03).

conclusionThe Midkine (+)/CEA (+) combination may be an indicator of poor prognosis for patients with colorectal cancer.

Indexed as

Biomarkers, TumorCarcinoembryonic AntigenColorectal NeoplasmsCytokinesNerve Growth FactorsAdultAgedAged, 80 and overCA-19-9 AntigenEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedMidkineNeoplasm StagingBiomarkers, TumorCA-19-9 AntigenCarcinoembryonic AntigenCytokinesMDK protein, humanMidkineNerve Growth FactorsCEAColorectal cancerMidkineSurvival

Identifiers

PMID40266400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.